Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Anjoli Zejdlik

Physician Assistant Milwaukee, WI Physician Assistant

NPI 1568933232 CMS profile 10696725

2350 N Lake Dr, Ste 501, Milwaukee, WI 53211

Open in the dashboard

General payments

$2,296

105 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Anjoli Zejdlik of Milwaukee, WI is reported in the CMS Open Payments database as having received $2,296 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $160 6
2022 General $1,017 41
2021 General $1,102 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anjoli Zejdlik
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Anjoli Zejdlik were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Anjoli Zejdlik Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,102 $132 $37–$438 $132
2022 $1,017 $155 $48–$522 $149
2023 $160 $167 $52–$557 $160
2024 $16 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $490 19 payments
  2. Agile Therapeutics, Inc. $280 18 payments
  3. Medtronic, Inc. $254 5 payments
  4. Evofem Biosciences, Inc. $211 13 payments
  5. Myovant Sciences Inc. $177 8 payments
  6. Astellas Pharma US Inc $137 3 payments
  7. Exeltis, USA Inc. $109 5 payments
  8. SCYNEXIS, Inc. $101 5 payments
  9. Avion Pharmaceuticals $87 6 payments
  10. Daiichi Sankyo Inc. $81 4 payments
  11. Other $370 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,198 104 payments
  2. Education $98 1 payment
Products named General payments · program years 2021–2024
  1. ORILISSA $403 15 payments
  2. ORIAHNN $302 16 payments
  3. Twirla $280 18 payments
  4. INTERSTIM $254 5 payments
  5. Phexxi $211 13 payments
  6. LO LOESTRIN FE $208 12 payments
  7. MYFEMBREE $177 8 payments
  8. SLYND $109 5 payments
  9. Balcoltra $87 6 payments
  10. INJECTAFER $81 4 payments
  11. Other $345 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

444

Median for Physician Assistant: 241

Drug cost

$187,259

Median for Physician Assistant: $4,110

Branded share of claims

59.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 190 $138,576
Gemtesa Vibegron Brand 39 $27,335
Estradiol Generic 102 $8,218
Premarin Estrogens, Conjugated Brand 16 $7,454
Methenamine Hippurate Generic 38 $2,414
Trospium Chloride Generic 17 $1,257
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 20 $1,178
Solifenacin Succinate Generic 22 $828

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,715

Medicare's payments for the services billed

Medicare patients

45

Average age 75

Services billed

50

45 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 62%
Ischemic heart disease 38%
Depression 33%
Osteoporosis 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record